



ishlt
academy

ADVANCED HEART FAILURE AND CARDIAC TRANSPLANTATION CORE COMPETENCIES

2:00 pm Saturday, April 24 – Noon Sunday, April 25
Waldorf Room, Hilton Chicago, Chicago, IL, USA
Chairs: James K. Kirklin, MD and Heather Ross, MD

SCIENTIFIC PROGRAM

SATURDAY, APRIL 24, 2010

2:00 pm Opening Remarks, James K. Kirklin, MD and Heather Ross, MD

SESSION 1: ADVANCED HEART FAILURE AND HIGH RISK SURGERY

2:10 pm **Advanced Heart Failure: Definitions and Prognosis, Heather Ross, MD**

current definitions, clinical phenotypes, and prognostic indices; CPET, biomarkers and survival scores

2:30 pm **Principles of Management in Decompensated Heart Failure, Heather Ross, MD**

epidemiology, review of trials with ino-dilators, diuretics, ultrafiltration; use of the PA catheter; ventilation; transition care to outpatient management

2:50 pm **Electrophysiological Considerations in Advanced Heart Failure, James B. Young, MD**

indications and outcomes for CRT, ICD and management of atrial fibrillation

3:10 pm **High Risk Surgery in Advanced Heart Failure, Frank Pagani, MD**

current state of art on mitral valve repair, ventricular remodeling and revascularization)

3:30 pm **Palliative Care in the Dying Heart Failure Patient, Heather Ross, MD**

principles of palliation, advanced directives and management of implanted devices

3:50 pm **Panel Discussion and Q & A, All Speakers**

4:05 pm **BREAK**

SESSION 2: MECHANICAL CIRCULATORY SUPPORT

4:20 pm **Definitions and Framework for MCS, Allen Anderson, MD**

definitions (BTT, BTC, and DT); bridge to recovery; CMS criteria)

4:40 pm **Patient Selection and Outcomes with MCS, Andreas Zuckermann, MD**

INTERMACS Classification, Lietz-Miller Risk Analysis of DT patients, SHFM and correlation of risk markers/co-morbidities and Outcomes with type of morbidity – RV failure, infection, neuro, death

5:05 pm **The Plethora of MCS Devices, Frank Pagani, MD**

centrifugal, pulsatile, axial, percutaneous, implantable, paracorporeal pumps; current FDA approved VADs and device durability; BiVads versus LVADs

5:25 pm Intraoperative and Early Post Operative Nuances, James Kirklin, MD

intraoperative key operative Techniques, use of TEE intraoperatively, RV function, suction events, ventricular arrhythmias and pulmonary hypertension

5:45 pm The Nuts and Bolts of Outpatient Management With an Implanted Device, Roberta Bogaev, MD

blood pressure assessment and management, anticoagulation regimens, GI bleeding, thromboembolic events, driveline Infections, non-device related infections

6:05 pm Panel Discussion and Q & A, All Speakers

6:20 pm BREAK

6:45 pm Buffet Dinner

SESSION 3: DINNER SESSION – PICTURES ARE WORTH A THOUSAND WORDS: IMAGING, BIOPSIES AND HEMODYNAMICS

7:00 pm Advanced Heart Failure Case, James Young, MD

7:20 pm Audience response and discussion

7:30 pm Mechanical Circulatory Support Case, James Kirklin, MD

7:50 pm Audience response and discussion

8:00 pm Cardiac Transplantation Cases, Jon Kobashigawa, MD

8:20 pm Audience response and discussion

8:30 pm Pulmonary Vascular Disease Cases, Paul Corris, FRCP

8:50 pm Audience response and discussion

SUNDAY, APRIL 25, 2010

7:00 am Continental Breakfast

SESSION 4: CARDIAC TRANSPLANTATION

7:30 am Issues in Determining Candidacy for Transplantation, James B. Young, MD

co-morbidities and their implications for heart transplantation listing, tobacco use, substance abuse and psychosocial evaluation in candidates, donor allocation algorithms

7:50 am Immunologic Considerations in Transplantation, James George, PhD

basic immunology, HLA matching, sensitization and desensitization regimens from an immune target perspective

8:10 am Critical Knowledge of Immunosuppression, Patricia Uber, PharmD

basic regimens, induction therapy, steroid regimens and adverse effects

8:30 am Essential Concepts in Rejection, Jon Kobashigawa, MD

cellular and antibody mediated rejection; antibody reducing regimens; desensitization for circulating antibodies

8:50 am Late Complications and Co-morbidities, Jayan Parameshwar, FRCP

hyperlipidemia, renal failure, cardiac allograft vasculopathy and cancer

9:10 am Panel Discussion and Q & A, All Speakers

9:30 am BREAK

SESSION 5: PULMONARY VASCULAR DISEASE

9:45 am Definitions, Pathogenesis, and Diagnosis, Paul Corris, FRCP

latest classification, genetic considerations, pathology, and targets for therapy; typical diagnostic tests and their limitations and interpretations

10:15 am The Pharmacological Treatment of PAH – State of the Art and End Point Targets, Myung Park, MD

Major landmark clinical trials in PAH; discussion of the implications and outcomes with current approved therapies; emerging therapies, new targets for therapy, and their potentials

10:40 am Practical Considerations, Pitfalls and Caveats of Drug Therapy, Patricia Uber, PharmD

drug adverse effects, considerations for dual and triple therapy, issues related to practical phenomenon including infection, platelet defects, rebound events

11:00 am Managing the Pharmacologically Refractory Patient, Paul Corris, FRCP

timing for lung transplantation, use of atrial septostomy, treatment of CTEPH

11:20 am Panel Discussion and Q & A, All Speakers

11:40 am CONCLUSION AND ADJOURN